Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 7:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 78 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Direct Acting Antivirals Clear all

Conditions: HEPATITIS C (HCV)
Interventions: PPP-CCM; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL/VOX, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chronic Hepatitis C Infection
Interventions: GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo; Drug · Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 36
States / cities: Phoenix, Arizona • Anaheim, California • La Jolla, California + 29 more

Conditions: Kidney Transplant, Hepatitis C, HCV
Interventions: Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hepatitis C, Chronic
Interventions: GS-5885, GS-9451, peginterferon alfa-2a, ribavirin tablet, GS-9451 Placebo; Drug · Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 21
States / cities: Tucson, Arizona • Beverly Hills, California • Coronado, California + 17 more

Conditions: Hepatitis C
Interventions: Direct Acting Antivirals; Drug
Lead sponsor: The Task Force for Global Health; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hepatitis C
Interventions: Methadone, DCV 3DAA FDC, BMS-791325, Buprenorphine, Naloxone; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 3
States / cities: Anaheim, California • Philadelphia, Pennsylvania • Salt Lake City, Utah

Conditions: Lung Diseases
Interventions: Zepatier, Epclusa; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 67 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Influenza
Interventions: Placebo for VNT-101, VNT-101; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Hepatitis C
Interventions: Direct Acting Antivirals; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Hepatitis C Virus
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 870 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 53
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 50 more

Conditions: Hepatitis C
Interventions: DCV/ASV/BMS-791325; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 42
States / cities: La Jolla, California • San Diego, California • San Francisco, California + 37 more

Conditions: Hepatitis C, HIV
Interventions: GS-7977/GS- 5885 FDC; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatitis C, Depression, PTSD, Substance Use Disorder, Fibrosis
Interventions: Brief mental health interventions and case management; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hepatitis C Virus Infection
Interventions: Voxilaprevir, Placebo to match voxilaprevir, SOF/VEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 10
States / cities: Costa Mesa, California • DeLand, Florida • Orlando, Florida + 7 more

Conditions: Hepatitis C
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hepatitis C, Opioid Use Disorder, IV Drug Usage
Interventions: Mobile Tele-HCV Care, Enhanced Usual Care; Other
Lead sponsor: Baystate Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Keene, New Hampshire • Bennington, Vermont • Brattleboro, Vermont

Conditions: Hepatitis C, Chronic
Interventions: midazolam, BI 201335, tenofovir, caffeine, tolbutamide, pegylated interferon, BI 207127, ribavirin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: La Mesa, California • Rockville, Maryland • Marlton, New Jersey + 2 more

Conditions: Hepatitis C, Chronic
Interventions: Sofosbuvir, Ledipasvir, GS-9669, GS-9451; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: HCV, Buprenorphine, PreP
Interventions: Evaluate model of care for HCV-infected adults with on-going opioid misuse; Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Batlimore, Maryland

Conditions: Chronic Hepatitis C Virus
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 441 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 53
States / cities: Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 50 more

Conditions: Chronic Hepatitis C
Interventions: Chlorcyclizine HCl, Ribavirin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Respiratory Failure, Hepatitis C
Interventions: Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatitis C, Chronic
Interventions: Not listed
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 65
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 53 more

Search by objective public record fields.

Hepatitis C Pharmacist, Physician, Patient Navigator Collaborative Care Model in Permanent Supportive Housing

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Utilization of Hepatitis C Positive Kidneys in Negative Recipients

GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus

The Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry

Drug Interaction & Methadone & Buprenorphine

Transplanting Hepatitis C Lungs Into Negative Lung Recipients

First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics

Hepatitis C Positive Donor Into Hepatitis C Negative Recipients

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects

Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV

Integrated Care for Patients With High Risk Substance Use and Psychiatric Disorder With Chronic Direct Acting Antiviral Treatment

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

Hepatitis C Pharmacy-based Strategy for Injectors

Rural New England Health Study (Phase 2)

Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

Combination Therapy for Chronic Hepatitis C Infection

Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection

Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C

Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant

An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1